In Aichi Cancer Center Hospital, we investigated the incidence of injection-site reactions associated with the administration of Oxaliplatin into a peripheral vein. We evaluated the frequency and severity of symptoms, and studied ways to manage its adverse reactions from September 2009 through March 2010. Oxaliplatin was injected into a peripheral vein in more than 90% of patients, suggesting that there would be a high risk of injection-site reactions. About 60% of patients had a numeric rating score of 5 or higher in this study, and more than 60% of injection-site reactions were improved by warming the injection site. Our results suggest that warming the injection site is one effective way to manage local adverse reactions when Oxaliplatin is administered into a peripheral vein.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database.
Sci Rep
December 2024
Department of Pharmacy, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, 215153, China.
Background: NK-1 receptor antagonists (NK-1RAs) are proven to be successful in preventing chemotherapy-induced nausea and vomiting (CINV). The safety profile of NK-1RAs has not been systematically analyzed in the real world. This pharmacovigilance study investigated the differences in adverse events (AEs) between NK-1RAs.
View Article and Find Full Text PDFPhase 1 study of AYP-101 (soybean phosphatidylcholine): safety, pharmacokinetics, and lipid profile effects for reducing submental fat.
Lipids Health Dis
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, 13620, Republic of Korea.
Background: Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.
View Article and Find Full Text PDFMajor adverse events associated with lipid reduction in inclisiran:a pharmacovigilance research of the FAERS database.
Expert Opin Drug Saf
December 2024
Department of Biochemistry, Chengde Medical University, Chengde, China.
Objective: The effectiveness and safety of the short-interfering RNA drug inclisiran in lowering patients' lipoprotein cholesterol levels to lower their risk of cardiovascular disease are presently being investigated. Based on the real-world adverse event report record in the FDA Adverse Event Reporting System, this article explores the occurrence and risk of adverse events during inclisiran treatment.
Research Design And Methods: We retrieved and screened all available data from the Food and Drug Administration website for the period from 2009 to the third quarter of 2023.
Optimal use of once-weekly basal insulin efsitora alfa in type 1 and type 2 diabetes: A systematic review and meta-analysis.
Endocr Pract
December 2024
Department of Endocrinology, Indraprastha Apollo Hospitals, New Delhi, Delhi 110076, India.
Objective: No meta-analysis has holistically analyzed and summarized the efficacy and safety of the novel once-weekly basal insulin efsitora alfa in managing type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: Clinical trials involving subjects with T1D and T2D receiving once-weekly efsitora alfa in the intervention arm and once-daily basal insulins in the control arm were searched throughout the electronic databases. The primary outcome assessed was the change from baseline in HbA1c.
Dermatological and nephrological complications after polymethyl methacrylate (PMMA) injections: a series of 239 cases.
J Am Acad Dermatol
December 2024
Universidade Estadual Paulista (UNESP), Botucatu-SP, Brazil.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!